FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer
NCT ID: NCT05810701
Last Updated: 2023-04-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
300 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-02-01
Study Completion Date
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Ovarian cancer (OC) is the fifth most common cause of cancer death. More than 40% are older than 70 years. The standard treatment is radical surgery combined with chemotherapy. More than 40% of the Danish patients will never undergo surgery. Frail and immunodeficient older patients are at higher risk of complications, and immunomodulating treatment as chemotherapy results in different outcomes in comparable patients. No accurate validated screening tool to identify frail and immunodeficient OC women exists. Optimization through comprehensive geriatric assessment (CGA) and physical training before and during treatment may improve outcomes and decrease associated risks.
Aim: Primary endpoints will be to determine whether a CGA and physical training vs standard of care can increase the proportion of patients later on referred to interval debulking surgery, and examine the performance of validated screening tests in predicting impairments in CGA. Other endpoints will be to evaluate if intervention can improve completion of chemotherapy, to examine the association between frailty screening scores and selected biomarkers with treatment outcomes, including complications and quality of life, and ultimately to develop an improved frailty screening tool based on known screening tools, functional tests and biomarkers identifying patients who will benefit from CGA.
Method: This is a nationwide, randomized intervention study. Patients ≥70 years diagnosed with primary OC at the Gynecological departments of Rigshospitalet, Odense and Roskilde University Hospitals will be included. In an interdisciplinary collaboration between medical specialists in oncology, gynecology and geriatrics, included patients will be screened for frailty using validated screening tools and functional tests. Specific biomarkers and immunologic profile will be assessed in all patients. Patients selected for neoadjuvant chemotherapy will be randomized to receive CGA or standard of care. Patients selected for primary debulking surgery or palliation will be followed in an observational cohort.
Perspective: The development of a validated screening tool for frailty assessment and immunological status will help us identify frail patients who may need optimization before treatment, resulting in more patients getting optimal treatment (either surgery or chemotherapy), prevent post-treatment complications and avoid palliative patients from undergoing a redundant complex treatment.
Aim: Primary endpoints will be to determine whether a CGA and physical training vs standard of care can increase the proportion of patients later on referred to interval debulking surgery, and examine the performance of validated screening tests in predicting impairments in CGA. Other endpoints will be to evaluate if intervention can improve completion of chemotherapy, to examine the association between frailty screening scores and selected biomarkers with treatment outcomes, including complications and quality of life, and ultimately to develop an improved frailty screening tool based on known screening tools, functional tests and biomarkers identifying patients who will benefit from CGA.
Method: This is a nationwide, randomized intervention study. Patients ≥70 years diagnosed with primary OC at the Gynecological departments of Rigshospitalet, Odense and Roskilde University Hospitals will be included. In an interdisciplinary collaboration between medical specialists in oncology, gynecology and geriatrics, included patients will be screened for frailty using validated screening tools and functional tests. Specific biomarkers and immunologic profile will be assessed in all patients. Patients selected for neoadjuvant chemotherapy will be randomized to receive CGA or standard of care. Patients selected for primary debulking surgery or palliation will be followed in an observational cohort.
Perspective: The development of a validated screening tool for frailty assessment and immunological status will help us identify frail patients who may need optimization before treatment, resulting in more patients getting optimal treatment (either surgery or chemotherapy), prevent post-treatment complications and avoid palliative patients from undergoing a redundant complex treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility of Frailty Assessment and Implementation of Interventions in Women Over 70 With Epithelial Ovarian Cancer
NCT04300699
Ovarian Cancer
Chemotherapy
Quality of Life
+2 more
UNKNOWN
NA
[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
NCT05903807
Ovarian Cancer
RECRUITING
PHASE2
Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV
NCT00231075
Ovarian Cancer
COMPLETED
PHASE2
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
NCT05574673
Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
RECRUITING
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
NCT01422265
Ovarian Cancer
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Introduction
Several studies have shown that a high percentage of patients with epithelial ovarian cancer (EOC) are undertreated due to their age, even in the absence of comorbidity. On the other hand, there seems to exist a group of frail patients unfit for extensive treatment that are over-treated. Therefore, it is of great interest to identify the group of older patients with EOC, who are frail and would benefit of a comprehensive geriatric assessment and optimisation, including individualised physical training. Unfortunately, no specific screening tool can be recommended or discouraged, and none of these tests are validated in patients with EOC.
Immunodeficiency and biomarkers regarding nutritional status, strength, and general health are not part of the standard evaluation, although several studies have shown a correlation between these factors and the functional independence of older patients, comorbidity, postoperative complications, tolerance to chemotherapy and quality of life.
In oncologic geriatrics a Comprehensive Geriatric Assessment (CGA - an examination performed by an interdisciplinary geriatric team) can be performed before start of treatment. Unfortunately, a complete CGA is both time and resource consuming, and the impact of interventions in older patients with EOC has never been examined.
Hypothesis and purpose
Our hypothesis is that frail patients with advanced ovarian cancer can benefit from a geriatric assessment and optimization, including physical training, increasing their chances of referral to surgery and to get full oncological treatment. The investigators believe that it is possible to develop a frailty screening tool with highly improved accuracy by combining known frailty screening tests, functional tests, and relevant biomarkers, which can help us select those patients who will benefit from a geriatric assessment and intervention.
The clinical study is parceled out in two working projects, WP1 and WP2, which are anchored at the departments of gynecology, geriatric medicine, and oncology at several centers in Denmark.
\- WP1: Geriatric assessment and intervention and its impact on treatment outcomes examined in a cohort of older patients with EOC referred to NACT Primary endpoint: To determine whether a CGA and tailored intervention vs. standard of care can increase the proportion of patients referred to IDS.
Secondary endpoints are a)to evaluate whether a CGA and tailored intervention can improve completion of chemotherapy, b) to investigate if CGA and a tailored intervention with physical training vs. standard of care improves treatment outcome and quality of life.
\- WP2: Impact of biomarkers, functional tests and immunological profile in assessing frailty and as predictors of adverse treatment outcomes in a national cohort of older EOC patients.
Primary endpoint: to examine the performance of three validated frailty screening tests (G8, mG8, and Clinical Frailty Index (CFI)) in EOC patients in predicting impairments in CGA.
Secondary endpoints are a)to examine whether adding functional tests, biomarkers, and the immunological profile can improve the accuracy of the frailty screening tests b) to examine whether the screening tool is predictive of patients achieving radical surgery and completing oncological treatment, as well as predict adverse treatment outcomes
Method description
The FRAGINOC project is a multicenter study, where WP1 is a clinical randomized trial of screening and intervention in older patients (≥70 years) with a diagnose of advanced EOC (FIGO stage III-IV). WP2 is a prospective observational study, where patients from WP1 will be asked to participate. Furthermore, older patients (≥70 years) referred to PDS or palliation will also be included. Patients will be evaluated at MDT conference, where they will be referred to either PDS and chemotherapy or NACT or palliation. Those referred to NACT will be re-evaluated at a second MDT conference after three cycles of chemotherapy to decide whether they can be referred to IDS.
Screening
All included patients will be screened for frailty after the MDT conference using a combination of the following tools:
* Questionnaires (Geriatric-8, modified Geriatric-8 and clinical frailty scale).
* Functional tests (hand grip test, 30 second chair test and 6 minutes walk test)
* Blood samples, which have all been validated previously although in other cancer types.
These tests will be repeated after the second MDT conference (after 3rd cycle of chemotherapy or before interval surgery)
Randomization and Intervention After the initial frailty screening, patients eligible for primary chemotherapy will be randomized 1:1 to CGA and tailored intervention or standard of care.
The intervention group will be evaluated by a geriatric specialist team examining different domains of their health status with the help of different validated questionnaires and tests, and tailored interventions will be made according to identified needs in the assessed health domains following the geriatric evaluation.
The intervention will specifically include a tailored-made physiotherapy training program of around 9-12 weeks duration, available in both physical and virtual versions. The program consists on supervised resistance training two days a week, either at hospital appointments or virtually from the patients' own home. Those patients who are not able to make the virtual training will be followed up by phone twice a week by the physiotherapist. Additionally, the training will be supported by a progressive walking program measured with a Garmin Vivofit 4 activity tracker. Patients will be thoroughly assessed by a physiotherapist during the training process. Nutritional supplements and advice on sufficient nutrition will be provided according to current clinical guidelines.
Patient-reported outcomes Measures (PROMs) All patients will be asked to complete the European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire - Ovarian Cancer Module (EORTC QLQ C-30, QLQ-OV28) and the supplemental Elderly Cancer Patients Module questionnaire (ELD-14), as well as European Quality of Life- 5 dimensions- 5 levels questionnaire (EQ-5D-5L for cost-utility analysis, at inclusion, after three cycles of chemotherapy, and at the end of treatment.
When assessing the quality of recovery, the QoR-15 questionnaire will be used and evaluated before surgery and 72 hours after PDS or IDS.
Statistical plan/recruitment consideration According to the literature and clinical experience, increasing the number of patients who receive surgery from the present 57 % to 77 % is clinically relevant and possible. To detect a difference of 20 % and obtain a type I error rate of 5% and a power of 80%, a sample size of 86 patients per study arm will be needed. To account for an expected dropout rate of \~20%, it was decided to increase this number to a group size of 100. Thus, a total of 206 patients referred to NACT will be included in the study (WP1 only). Patients referred to PDS will be followed in an observational design. For the last three years, 130 patients fulfilling the inclusion criteria have been treated at RH, OUH, HUH, and SUH each year. Thus, inclusion is expected to run over 2-3 years.
Data will be collected prospectively (demographic, clinical, pathologic, and results from frailty screening, functional tests, blood tests, and intervention effects), and recorded in predesigned RedCap. PRO will be completed by the patients either electronically and registered directly in RedCap, by phone calls or delivered in hand to the Ph.D. student or research nurses. Life-long follow-up data on overall survival will be obtained from the Danish Hospital Registry through linkage with a personal identification number.
Logistic regression will be used to evaluate change over time in ordinal categorical values. Independent T-tests will be used to evaluate in-group and between-groups differences. Kaplan-Meier method and Cox regression analyses will be used to analyze Progression Free Survival.
Several studies have shown that a high percentage of patients with epithelial ovarian cancer (EOC) are undertreated due to their age, even in the absence of comorbidity. On the other hand, there seems to exist a group of frail patients unfit for extensive treatment that are over-treated. Therefore, it is of great interest to identify the group of older patients with EOC, who are frail and would benefit of a comprehensive geriatric assessment and optimisation, including individualised physical training. Unfortunately, no specific screening tool can be recommended or discouraged, and none of these tests are validated in patients with EOC.
Immunodeficiency and biomarkers regarding nutritional status, strength, and general health are not part of the standard evaluation, although several studies have shown a correlation between these factors and the functional independence of older patients, comorbidity, postoperative complications, tolerance to chemotherapy and quality of life.
In oncologic geriatrics a Comprehensive Geriatric Assessment (CGA - an examination performed by an interdisciplinary geriatric team) can be performed before start of treatment. Unfortunately, a complete CGA is both time and resource consuming, and the impact of interventions in older patients with EOC has never been examined.
Hypothesis and purpose
Our hypothesis is that frail patients with advanced ovarian cancer can benefit from a geriatric assessment and optimization, including physical training, increasing their chances of referral to surgery and to get full oncological treatment. The investigators believe that it is possible to develop a frailty screening tool with highly improved accuracy by combining known frailty screening tests, functional tests, and relevant biomarkers, which can help us select those patients who will benefit from a geriatric assessment and intervention.
The clinical study is parceled out in two working projects, WP1 and WP2, which are anchored at the departments of gynecology, geriatric medicine, and oncology at several centers in Denmark.
\- WP1: Geriatric assessment and intervention and its impact on treatment outcomes examined in a cohort of older patients with EOC referred to NACT Primary endpoint: To determine whether a CGA and tailored intervention vs. standard of care can increase the proportion of patients referred to IDS.
Secondary endpoints are a)to evaluate whether a CGA and tailored intervention can improve completion of chemotherapy, b) to investigate if CGA and a tailored intervention with physical training vs. standard of care improves treatment outcome and quality of life.
\- WP2: Impact of biomarkers, functional tests and immunological profile in assessing frailty and as predictors of adverse treatment outcomes in a national cohort of older EOC patients.
Primary endpoint: to examine the performance of three validated frailty screening tests (G8, mG8, and Clinical Frailty Index (CFI)) in EOC patients in predicting impairments in CGA.
Secondary endpoints are a)to examine whether adding functional tests, biomarkers, and the immunological profile can improve the accuracy of the frailty screening tests b) to examine whether the screening tool is predictive of patients achieving radical surgery and completing oncological treatment, as well as predict adverse treatment outcomes
Method description
The FRAGINOC project is a multicenter study, where WP1 is a clinical randomized trial of screening and intervention in older patients (≥70 years) with a diagnose of advanced EOC (FIGO stage III-IV). WP2 is a prospective observational study, where patients from WP1 will be asked to participate. Furthermore, older patients (≥70 years) referred to PDS or palliation will also be included. Patients will be evaluated at MDT conference, where they will be referred to either PDS and chemotherapy or NACT or palliation. Those referred to NACT will be re-evaluated at a second MDT conference after three cycles of chemotherapy to decide whether they can be referred to IDS.
Screening
All included patients will be screened for frailty after the MDT conference using a combination of the following tools:
* Questionnaires (Geriatric-8, modified Geriatric-8 and clinical frailty scale).
* Functional tests (hand grip test, 30 second chair test and 6 minutes walk test)
* Blood samples, which have all been validated previously although in other cancer types.
These tests will be repeated after the second MDT conference (after 3rd cycle of chemotherapy or before interval surgery)
Randomization and Intervention After the initial frailty screening, patients eligible for primary chemotherapy will be randomized 1:1 to CGA and tailored intervention or standard of care.
The intervention group will be evaluated by a geriatric specialist team examining different domains of their health status with the help of different validated questionnaires and tests, and tailored interventions will be made according to identified needs in the assessed health domains following the geriatric evaluation.
The intervention will specifically include a tailored-made physiotherapy training program of around 9-12 weeks duration, available in both physical and virtual versions. The program consists on supervised resistance training two days a week, either at hospital appointments or virtually from the patients' own home. Those patients who are not able to make the virtual training will be followed up by phone twice a week by the physiotherapist. Additionally, the training will be supported by a progressive walking program measured with a Garmin Vivofit 4 activity tracker. Patients will be thoroughly assessed by a physiotherapist during the training process. Nutritional supplements and advice on sufficient nutrition will be provided according to current clinical guidelines.
Patient-reported outcomes Measures (PROMs) All patients will be asked to complete the European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire - Ovarian Cancer Module (EORTC QLQ C-30, QLQ-OV28) and the supplemental Elderly Cancer Patients Module questionnaire (ELD-14), as well as European Quality of Life- 5 dimensions- 5 levels questionnaire (EQ-5D-5L for cost-utility analysis, at inclusion, after three cycles of chemotherapy, and at the end of treatment.
When assessing the quality of recovery, the QoR-15 questionnaire will be used and evaluated before surgery and 72 hours after PDS or IDS.
Statistical plan/recruitment consideration According to the literature and clinical experience, increasing the number of patients who receive surgery from the present 57 % to 77 % is clinically relevant and possible. To detect a difference of 20 % and obtain a type I error rate of 5% and a power of 80%, a sample size of 86 patients per study arm will be needed. To account for an expected dropout rate of \~20%, it was decided to increase this number to a group size of 100. Thus, a total of 206 patients referred to NACT will be included in the study (WP1 only). Patients referred to PDS will be followed in an observational design. For the last three years, 130 patients fulfilling the inclusion criteria have been treated at RH, OUH, HUH, and SUH each year. Thus, inclusion is expected to run over 2-3 years.
Data will be collected prospectively (demographic, clinical, pathologic, and results from frailty screening, functional tests, blood tests, and intervention effects), and recorded in predesigned RedCap. PRO will be completed by the patients either electronically and registered directly in RedCap, by phone calls or delivered in hand to the Ph.D. student or research nurses. Life-long follow-up data on overall survival will be obtained from the Danish Hospital Registry through linkage with a personal identification number.
Logistic regression will be used to evaluate change over time in ordinal categorical values. Independent T-tests will be used to evaluate in-group and between-groups differences. Kaplan-Meier method and Cox regression analyses will be used to analyze Progression Free Survival.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Ovarian Cancer
Frailty
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Rancomized clinical trial Combined observational study
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NACT and CGA+ physical training intervention
Elderly (≥70 years) ovarian cancer patients referred for Neo-adjuvant treatment randomized to comprehensive geriatric assessment and individualised physical training.
Group Type
ACTIVE_COMPARATOR
Comprehensive geriatric assessment and individualised physical training
Intervention Type
OTHER
Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
NACT no intervention
Elderly (≥70 years) ovarian cancer patients referred for Neo-adjuvant treatment randomized to standard of care
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Comprehensive geriatric assessment and individualised physical training
Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosed ovarian cancer
* Capable of understanding written and oral danish
* Capable of understanding written and oral danish
Exclusion Criteria
* Other active cancers in the preceding 5 years
* Severe psychiatric disease
Patients referred to primary debulking surgery will be followed in a observational design
* Severe psychiatric disease
Patients referred to primary debulking surgery will be followed in a observational design
Minimum Eligible Age
70 Years
Maximum Eligible Age
120 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Sponsor Role
collaborator
Herlev Hospital
OTHER
Sponsor Role
collaborator
Zealand University Hospital
OTHER
Sponsor Role
collaborator
Odense University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tine Henrichsen Schnack
MD, PhD, Associate Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Odense University Hospital
Odense, Region of South Denmark, Denmark
Site Status
RECRUITING
Vejle Hospital
Vejle, Region of South Denmark, Denmark
Site Status
RECRUITING
Zealand University Hospital
Roskilde, Region Sjælland, Denmark
Site Status
RECRUITING
Copenhagen University Hospital Rigshospitalet
Copenhagen, The Capital Region of Denmark, Denmark
Site Status
RECRUITING
Herlev and Gentofte Hospital
Herlev, The Capital Region of Denmark, Denmark
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Denmark
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OUHAgeCareOvarian
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
NCT01366183
UNKNOWN
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00719303
UNKNOWN
PHASE3
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
NCT01391351
COMPLETED
NA
Genomic BRCA and Extensive ovArian Cancer Testing
NCT04027868
COMPLETED
Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)
NCT00239980
COMPLETED
PHASE2
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472
COMPLETED
Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)
NCT01696994
ACTIVE_NOT_RECRUITING
NA
Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer
NCT04830709
RECRUITING
Patient-Reported Outcomes Among Women Wtih Gynecological Cancer (The CONNECT Study)
NCT04945187
UNKNOWN
NA
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01080521
COMPLETED
Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation
NCT05763472
UNKNOWN
New Biomarkers Evaluating Ovarian Cancer
NCT01466049
COMPLETED
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
NCT00443196
COMPLETED
PHASE2/PHASE3
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00288275
TERMINATED
A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation
NCT05918042
ACTIVE_NOT_RECRUITING
Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India
NCT03471572
COMPLETED
Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy
NCT06588322
RECRUITING
NA
Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer
NCT02406235
COMPLETED
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT05542407
RECRUITING
PHASE1
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT01381861
COMPLETED
PHASE2
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
NCT04742075
RECRUITING
PHASE2
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02446600
ACTIVE_NOT_RECRUITING
PHASE3
The Immune Landscape of Epithelial Ovarian Cancer
NCT05984875
RECRUITING